After almost 10 years of service as the CEO of Tegra Medical and as Head of the Medical division within the SFS Group, J. Mark King has decided to retire as of August 1, 2020. The Board of Directors and the Group Executive Board thank J. Mark King for his many years of service, his contribution to the development of Tegra Medical and its integration into the SFS Group.
The MedTech industry is an important market segment for the SFS Group. It is the strategic goal to further strengthen and to grow SFS’ position through the Tegra Medical brand in the MedTech market. Substantial investments in people and capacities are planned in order to pursue this goal.